Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials.

ABSTRACT:

Purpose

To assess different microperimetry (MP) macular sensitivity outcome measures capturing functional deterioration in eyes with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Design

Patients were included from 2 identically designed, phase III, double-masked, randomized controlled clinical trials, Chroma (NCT02247479) and Spectri (NCT02247531).

Participants

Patients enrolled were aged ≥ 50 years with bilateral GA and no evidence of previous or active neovascular AMD.

Methods

Patients were randomized 2:1:2:1 to receive through 96 weeks intravitreal lampalizumab 10 mg every 4 weeks (LQ4W), every 6 weeks (LQ6W), or corresponding sham procedures. For this study, mesopic macular sensitivity of the central 20° was assessed using MP-

SUBMITTER: Chang DS 

PROVIDER: S-EPMC10587617 | biostudies-literature | 2024 Jan-Feb

REPOSITORIES: biostudies-literature